Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;7(10):e2438398.
doi: 10.1001/jamanetworkopen.2024.38398.

Combined Methylphenidate and Selective Serotonin Reuptake Inhibitors in Adults With Attention-Deficit/Hyperactivity Disorder

Dong Yun Lee  1   2 , Chungsoo Kim  3 , Yunmi Shin  4 , Rae Woong Park  1   5
Affiliations

Combined Methylphenidate and Selective Serotonin Reuptake Inhibitors in Adults With Attention-Deficit/Hyperactivity Disorder

Dong Yun Lee et al. JAMA Netw Open. .

Abstract

Importance: Depression is a common comorbidity of adult attention-deficit/hyperactivity disorder (ADHD), and the combination of methylphenidate and selective serotonin reuptake inhibitors (SSRIs) is a frequently prescribed treatment. However, there is limited clinical evidence on the safety of this medication combination in adults with ADHD.

Objective: To evaluate the safety of administering a combination of SSRI and methylphenidate in adults with ADHD and comorbid depression.

Design, setting, and participants: This cohort study obtained data from a nationwide claims database in South Korea from January 2016 to February 2021. Participants were adults aged 18 years or older with a diagnosis of ADHD and depressive disorder who were prescribed methylphenidate. Comparisons of 4 groups who received prescriptions were conducted: (1) SSRI plus methylphenidate (hereafter, SSRI) group vs methylphenidate-only group and (2) methylphenidate plus fluoxetine (hereafter, fluoxetine) group vs methylphenidate plus escitalopram (hereafter, escitalopram) group (compared to find a preferable treatment option). Data analysis was conducted between July and December 2023.

Exposures: New users of the methylphenidate and SSRI combination among adults with both ADHD and depressive disorder.

Main outcomes and measures: A total of 17 primary and secondary outcomes, including neuropsychiatric and other events, were assessed, with respiratory tract infection used as a control outcome. Groups were matched at a 1:1 ratio using a propensity score to balance confounders. A Cox proportional hazards regression model was used to calculate hazard ratio (HRs) and 95% CIs. Subgroup analysis by sex and sensitivity analyses in varying epidemiologic settings were conducted.

Results: The study included 17 234 adults with ADHD (mean [SD] age at study entry, 29.4 [10.8] years; 9079 females [52.7%]). There was no difference in the risk of outcomes between the methylphenidate-only and SSRI groups, except for a lower risk of headache in the SSRI group (HR, 0.50; 95% CI, 0.24-0.99). In sensitivity analyses of fluoxetine vs escitalopram, the risk of hypertension (HR: 1:n matching, 0.26; 95% CI, 0.08-0.67) and hyperlipidemia (HR: 1:n matching, 0.23; 95% CI, 0.04-0.81) was lower in the fluoxetine group than in the escitalopram group.

Conclusions and relevance: Results of this study revealed no significant increase in adverse event risk associated with use of SSRI plus methylphenidate vs methylphenidate alone in adults with ADHD and comorbid depression. Instead, the combination was associated with a lower risk of headache.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Kim reported receiving personal fees from IQVIA outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Forest Plots of Outcome Estimates of Selective Serotonin Reuptake Inhibitor (SSRI) Plus Methylphenidate (MPH) vs MPH-Only Groups and Fluoxetine vs Escitalopram Groups
Neuropsychiatric outcomes include attention-deficit/hyperactivity disorder (ADHD) hospitalization, mania, anxiety disorder, sleep disorder, and tic disorder. Error bars represent 95% CIs.
Figure 2.
Figure 2.. Comparison of Headache Between the Selective Serotonin Reuptake Inhibitor (SSRI) Plus Methylphenidate (MPH) Group and MPH-Only Group
AT indicates as treated; PS, propensity score; ITT, intention to treat; and 1:n, 1 to maximum matching. Error bars represent 95% CIs.
See this image and copyright information in PMC

References

    1. Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194(3):204-211. doi:10.1192/bjp.bp.107.048827 - DOI - PubMed
    1. Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020;395(10222):450-462. doi:10.1016/S0140-6736(19)33004-1 - DOI - PMC - PubMed
    1. Bálint S, Czobor P, Komlósi S, Mészáros A, Simon V, Bitter I. Attention deficit hyperactivity disorder (ADHD): gender- and age-related differences in neurocognition. Psychol Med. 2009;39(8):1337-1345. doi:10.1017/S0033291708004236 - DOI - PubMed
    1. Faraone SV, Asherson P, Banaschewski T, et al. . Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. 2015;1(1):15020. doi:10.1038/nrdp.2015.20 - DOI - PubMed
    1. Katzman MA, Bilkey TS, Chokka PR, Fallu A, Klassen LJ. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry. 2017;17(1):302. doi:10.1186/s12888-017-1463-3 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances